Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04165031
Title A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

Therapies

Cetuximab + LY3499446

Erlotinib + LY3499446

LY3499446

Abemaciclib + LY3499446

Docetaxel

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.